Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy

11 Jun 2024 07:00 CEST

Oslo, Norway, June 11, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced updates on its mRNA
platform at the Cancer Immunotherapy meeting in Boston. The company highlighted
the significant advantages of its innovative APC-targeted neoantigen vaccine,
delivered in a mRNA-lipid nanoparticle (LNP) format.

This latest study demonstrated that the APC-targeted vaccine consistently
achieved a broader and more robust immune response across doses compared to an
untargeted neoantigen vaccine. It also provided superior tumor control and
resulted in dramatically improved survival rates in a mouse model of colorectal
cancer.

Chief Scientific Officer, Agnete Fredriksen, commented on the findings, "Our
latest data not only emphasize the effectiveness of the APC-targeted approach
but also confirm our platform's potential across modalities to significantly
advance the treatment landscape for cancer. The strong data demonstrating
Nykode’s potential to improve mRNA vaccines underscore our commitment to leading
the way in next-generation immunotherapies."

Nykode presented a poster detailing these findings at the meeting, with further
information available on the Nykode website:
https://nykode.com/research-and-development/scientific-papers-and-presentations.

Nykode remains dedicated to pushing the boundaries of cancer treatment and
improving patient outcomes through innovative research and development.


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology
specifically targets antigens to antigen presenting cells (APC), employed with
their cancer vaccines to induce a broad, strong and long-lasting antigen
specific immune response, which correlates with clinical responses in cancer
patients.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies, which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer.
VB10.16 is being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer, including the potential registrational trial of
VB10.16 in HPV16-positive cervical cancer. VB10.NEO, an individualized cancer
neoantigen vaccine, is exclusively out-licensed to Genentech, a member of the
Roche Group.

The Company’s partnerships include Genentech within oncology, and a multi-target
collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse
vaccine platform for the potential use in autoimmune disorders, organ transplant
rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

More information:
Access the news on Oslo Bors NewsWeb site

621130_240611_mRNA platform update - PR_FINAL.pdf